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Abstract
Background:  Most testicular germ cell tumors arise from intratubular germ cell neoplasia
unclassified (IGCNU, also referred to as carcinoma in situ), which is thought to originate from a
transformed primordial germ cell (PGC)/gonocyte, the fetal germ cell. Analyses of the molecular
profile of IGCNU and seminoma show similarities to the expression profile of fetal germ cells/
gonocytes. In murine PGCs, expression and interaction of Blimp1 and Prmt5 results in arginine 3
dimethylation of histone H2A and H4. This imposes epigenetic modifications leading to
transcriptional repression in mouse PGCs enabling them to escape the somatic differentiation
program during migration, while expressing markers of pluripotency.
Results: In the present study, we show that BLIMP1 and PRMT5 were expressed and arginine
dimethylation of histones H2A and H4 was detected in human male gonocytes at weeks 12–19 of
gestation, indicating a role of this mechanism in human fetal germ cell development as well.
Moreover, BLIMP1/PRMT5 and histone H2A and H4 arginine 3 dimethylation was present in
IGCNU and most seminomas, while downregulated in embryonal carcinoma (EC) and other
nonseminomatous tumors.
Conclusion: These data reveal similarities in marker expression and histone modification between
murine and human PGCs. Moreover, we speculate that the histone H2A and H4 arginine 3
dimethylation might be the mechanism by which IGCNU and seminoma maintain the
undifferentiated state while loss of these histone modifications leads to somatic differentiation
observed in nonseminomatous tumors.
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Background
In males aged 15 – 34 years, type II testicular germ cell
tumors (TGCT), i.e. seminomas and nonseminomas, are
the most common malignancies with fatal outcome [1]
accounting for up to 60% of all malignancies in young
man. The incidence of this type of cancer has been steadily
increasing throughout the last decades [2]. The tumors
arise from a neoplastic precursor, the carcinoma in situ
(CIS)/intratubular germ cell neoplasia unclassified (IGCNU)
and develop into seminoma and/or nonseminoma
(including embryonal carcinoma, teratomas, yolk sac
tumors and choriocarcinomas) [3]. The IGCNU lesions
are believed to arise by delayed or blocked maturation of
primordial germ cells (PGC)/gonocytes during early fetal
development [4]. The recently identified markers for
IGCNU and seminoma, namely the markers of pluripo-
tency OCT3/4 and NANOG further support this model [5-
10].
Expression of pluripotency genes is detected in embryonic
stem cells (ES) and the inner cell mass of the early
embryo. Additionally murine and human ES cells need to
be cultured in the presence of factors inhibiting differenti-
ation, although there are species specific differences
[11,12]. In PGCs, early gonocytes and IGCNU as well as
seminoma lesions some of these markers of pluripotency
are expressed, although differences have been reported
[13,14]. According to the current model, PGCs actively
suppress somatic differentiation programs by epigenetic
modifications, a mechanism which might also account for
IGCNU and seminoma [15]. Recent data in mice demon-
strate that suppression of somatic differentiation pro-
grams in PGCs is mediated by a complex of two proteins,
Blimp1 (B-Lymphocyte induced maturation protein-1;
PRDM1) and Prmt5 (protein arginine methyltransferase-
5). Upon arrival in the genital ridge the PGCs differentiate
to become gonocytes and the Blimp1/Prmt5 complex is
translocated in the cytoplasm and subsequently, Blimp1
is downregulated. Targeted deletion of Blimp1 leads to
loss of PGCs short after specification due to differentia-
tion. The Blimp1-deficient PGCs display an insufficient
repression of markers indicative for somatic differentia-
tion such as HoxB1  [16]. Blimp1 is a transcriptional
repressor harboring an N-terminal PR-SET domain, 5
zinc-finger domains and an acidic domain at the C-termi-
nus. In murine PGCs the Blimp1/Prmt5 complex medi-
ates symmetrical methylation of histones H2A and H4 at
arginine 3 (H2AR3me2s, H4R3me2s), resulting in wide-
spread epigenetic modification leading to transcriptional
repression [17].
In the present study, we investigated the expression of
BLIMP1/PRMT5 during human fetal germ cell develop-
ment and in testicular germ cell tumors. Analyzing human
fetal tissues, we found BLIMP1/PRMT5 colocalized in
gonocytes at weeks 12 – 19 of pregnancy, supporting a
role in human germ cell development. Furthermore
BLIMP1/PRMT5 is expressed in IGCNU and seminoma,
but downregulated in nonseminomatous GCTs. Since the
nuclear localization of BLIMP1 correlated with the pres-
ence of the histone modifications H2AR3me2s and
H4R3me2, our data help in explaining the undifferenti-
ated/fetal state of IGCNU and seminoma.
Results
Normal germ cell development
Data from murine embryos indicate, that the murine
homologs of BLIMP1 and PRMT5, are expressed in PGCs
from specification on up to their arrival in the genital
ridge [16,17]. Short thereafter, these cells differentiate to
become gonocytes and the Blimp1/Prmt5 complex is
translocated in the cytoplasm and subsequently, Blimp1
is downregulated. In order to test whether human BLIMP1
and PRMT5 are detected in human fetal PGCs/gonocytes,
immunohistochemical analyses were performed on
human fetal material. On the 12th week of pregnancy
migrating gonocytes coexpressing PRMT5 and BLIMP1
were detected, (Fig. 1, compare A to B, merged in C,
arrows). Next, testes from the 19th week of pregnancy were
analyzed. By this time gonocytes gradually differentiate
into prespermatogonia and migrate towards the periphery
of the emerging seminiferous tubules to settle down in
their niche [18]. Both BLIMP1 (Fig. 2A) and PRMT5 (Fig.
2B) were detected at this stage in gonocytes. PRMT5, in
contrast to BLIMP1, was detected both in the nucleus and
in the cytoplasm. Since the murine Blimp1/Prmt5 com-
plex has been described to mediate symmetrical dimeth-
ylation of arginine 3 on histone H2A and/or H4 tails
(H2AR3me2s/H4R3me2s) [17] immunohistochemical
analysis to detect this modification was performed (Fig.
2D). Co-staining of PRMT5 revealed that the cells display-
ing high nuclear levels of PRMT5 are in fact positive for
the H2AR3me2s/H4R3me2s histone mark (Fig. 2E and
2F, merged). To further analyze the population of cells
expressing BLIMP1 we performed double labeling experi-
ments using BLIMP1 (Figure 2G) and the gonocytal mark-
ers M2A[19] (Figure 2H). BLIMP1/M2A double positive
signals were detected in most gonocytes (Figure 2I,
arrows). Double labeling for H2AR3me2s/H4R3me2s
(Fig 2K) combined with M2A (Fig. 2L) showed, that the
M2A positive gonocytes displayed H2AR3me2s/
H4R3me2s modifications (Fig 2M). Again, these findings
were in accordance with the situation in mice, where the
Blimp1 protein is downregulated and the H2AR3me2s/
H4R3me2s methylation is gradually lost when germ cells
proceed to prespermatogonia [17].
Since the murine Blimp1/Prmt5 complex was specifically
detected in early germ cells but not in prespermatogo-
nia[16] we next asked whether PRMT5, BLIMP1 andBMC Developmental Biology 2008, 8:106 http://www.biomedcentral.com/1471-213X/8/106
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dimethylated histone H2A and H4 could be detected in
adult human testes. BLIMP1 was detected in the cyto-
plasm of round spermatids (Fig. 3A, arrow) and PRMT5
was found in the nuclei and in the cytoplasm of sperma-
tocytes (Fig. 3B arrow) and round spermatids (Fig. 3B
black arrowhead). H2AR3me2s/H4R3me2s modification
is detected in type A spermatogonia (Fig. 3C red arrow-
head), as well as round and elongated spermatids, (Fig.
3C arrow). The cytoplasmatic localization of BLIMP1 in
adult testes excludes the functional interaction with
PRMT5 and the resulting epigenetic modification. This
implicates an alternative mechanism of H2AR3me2s/
H4R3me2s modification in adult testes.
Type II TGCTs
We next examined various TGCTs for the presence of
BLIMP1/PRMT5 and H2AR3me2s/H4R3me2s. As shown
in Figure 4, IGCNU show nuclear BLIMP1 staining (Fig.
4A), cytoplasmatic PRMT5 staining (Fig. 4B) and dimeth-
ylation of H2A/H4 (Fig. 4C). Seminomas show predomi-
nant nuclear BLIMP1 signal (Fig. 4D) sparse nuclear
PRMT5 signal (Fig. 4E) as well as a strong and homoge-
nous signal for H2AR3me2s/H4R3me2s (Fig 4F). In
embryonal carcinoma, expression of BLIMP1 (Fig. 4G)
and PRMT5 (Fig. 4H) was weak and cytoplasmatic. As
expected, histone H2AR3me2s/H4R3me2s methylation
(Fig. 4I) was barely detectable and heterogeneous. Yolk
sac tumors teratomas and choriocarcinomas stained
focally and cytoplasmatic for BLIMP1 and PRMT5 (not
shown). Focal cytoplasmatic expression of BLIMP1 and
PRMT5 was also observed in differentiated parts of ter-
atoma, while chorioncarcinomas were negative for both
proteins. A summary of the results of the immunohisto-
chemical studies is given in Table 1.
In order to quantify the expression of BLIMP1 and PRMT5
we performed RT-PCR analyses on normal testicular tissue
as well as on various TGCTs. The RNA levels measured
were first normalized to βActin and then calculated as rel-
ative expression with normal testicular tissue (N) set at 1.
Expression of BLIMP1 was significantly higher in IGCNU
(p = 0.029) containing testicular parenchyma and semi-
noma (Fig. 4K), but not in embryonal carcinoma (EC) (p
= 0.16), which was comparable to normal testicular tissue.
In contrast, PRMT5 was moderately higher in IGCNU (p =
0.033), while embryonal carcinoma (p = 0,091) and sem-
inoma (p = 0,091) express a similar level of PRMT5 com-
pared to normal testicular tissue (Fig. 4L). These data
Human fetal gonocytes at 12th week of pregnancy Figure 1
Human fetal gonocytes at 12th week of pregnancy. Sections of human fetal gonocytes at 12th week of pregnancy sub-
jected to antibody staining towards BLIMP1 (A), PRMT5 (B) and overlay (C). D and E no primary antibody controls. Arrows 
indicate exemplary germ cells. Bar = 50 μm.BMC Developmental Biology 2008, 8:106 http://www.biomedcentral.com/1471-213X/8/106
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Human fetal gonocytes at 19th week of pregnancy Figure 2
Human fetal gonocytes at 19th week of pregnancy. Sections of human fetal gonocytes at 19th week of pregnancy sub-
jected to antibody staining towards (A) BLIMP1, (B) PRMT5, (C) Merge of BLIMP1 and PRMT5, (D) PRMT5, (E) methylated 
H2A/H4, (F) merge of PRMT5 and methylated H2A/H4 (G) BLIMP1 (H) M2A antigen, (I) merge of BLIMP1 and M2A, (K) 
methylated H2A/H4, (L) M2A, (M) merge of methylated H2A/H4 and M2A.BMC Developmental Biology 2008, 8:106 http://www.biomedcentral.com/1471-213X/8/106
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Human adult testis Figure 3
Human adult testis. Sections of normal human adult testis stained for BLIMP1 (A), PRMT5 (B) methylated and dimethylated 
histones H2A/H4 (C). (A) A seminiferous tubule is shown with normal spermatogenesis. Spermatogonia, spermatocytes, and 
Sertoli cells are devoid of the staining, while nuclear and cytoplasmatic staining occurs in round spermatids (large arrow). (B) 
Staining with PRMT5 antibody shows low expression of PRMT5 in the nuclei of spermatocytes (arrowhead), and strong nuclear 
staining in round spermatids (large arrow). (C) Positive staining with Me H2A/H4 occurs in spermatogonia (red arrowheads) 
and round spermatids (arrow), but not in spermatocytes. lu lumen of the seminiferous tubule; Le Leydig Cells.BMC Developmental Biology 2008, 8:106 http://www.biomedcentral.com/1471-213X/8/106
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Human germ cell tumors Figure 4
Human germ cell tumors. Sections of neoplastic germ cells of IGCNU (A-C), seminoma (D-F), embryonal carcinoma (G-
I) stained for BLIMP1 (A, D, G), PRMT5 (B, E, and H) and methylated histones H2A/H4 (C, F, I). In Figure A-C tubules with 
IGCNU are shown with consistent nuclear expression of BLIMP1 and Me H2A/H4 in neoplastic germ cells (A, BLIMP1; C, Me 
H2A/H4). PRMT5 is expressed in the cytoplasm of neoplastic germ cells (B). Notice that no expression is present in Sertoli 
cells. In Figures D-F expression in seminomas is presented. Notice the variation of the expression of BLIMP1, being low or 
moderate in the majority of the cells (D). PRMT5 is expressed in the cytoplasm of most seminoma cells, but some neoplastic 
cells also show nuclear staining (E). Figure F shows a strong nuclear staining of MeH2A/H4 in most seminoma cells. Size bar is 
50 μm. Quantification of the relative expression of BLIMP1 (K) and PRMT5 (L) normalized to β-Actin and compared to normal 
testicular tissue. Bars above the graph indicate p-values. (M, N) Expression values for BLIMP1 (M) and PRMT5 (N) from inde-
pendent Affymetrix expression analyses (as referred in 23). Data are plotted as Log2 (y-axis) after normalization. Abbrevia-
tions: Normal testicular tissue (N), IGCNU, seminoma (SE), embryonal carcinoma (EC).BMC Developmental Biology 2008, 8:106 http://www.biomedcentral.com/1471-213X/8/106
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could be confirmed, using a whole genome expression
DNA-Array as reported before [20]. Here, the same pattern
was observed (see Fig. 4M and 4N).
Finally, we asked whether BLIMP1/PRMT5 and modifica-
tion of histone H2A and H4 could be detected in TCam-2,
a cell line derived from a seminoma patient [21,22]. Here,
we were able to detect BLIMP1 in the nucleus, PRMT5 in
the nucleus and the cytoplasm (Fig. 5A–C). RT-PCR anal-
yses showed that BLIMP1 and PRMT5 are expressed in
TCam-2 cells (Fig. 5E) and absent JKT1 cells, in agreement
with Affymetrix data (Fig. 4M and 4N). Of note, the find-
ings on the JKT-1 cell line are in concordance with the
conclusion that it is not a seminoma cell line [22,23].
Western blot analysis confirmed these results, showing
that BLIMP1 and PRMT5, as well as the modified Histones
H2A and H4 (Fig. 5F) can be detected. Next, we per-
formed a CoIP on extracts from TCam-2 cells and were
able to detect a signal for Blimp1 in material immunopre-
cipitated with PRMT5 antibody (Fig. 5G). This result dem-
onstrates for the first time that PRMT-5 and BLIMP-1
interact biochemically.
We had shown, that nuclear BLIMP1 and methylated H2A
and H4 are expressed in IGCNU and seminoma, yet these
cells express either little or cytoplasmic PRMT5 (Fig. 4A–
F). We speculated that another methytransferase cooper-
ating with BLIMP1 might be able to compensate PRMT5
function and help in establishing this methylation pat-
tern. PRMT7 which is like PRMT5 a type II methyltrans-
ferase seemed a potential candidate since both PRMT5
and PRMT7 have been demonstrated to mediate symmet-
ric arginine dimethylation of sm Proteins required for the
spliceosome [24]. The CoIP experiment (Fig. 4H), dem-
onstrates that BLIMP1 and PRMT7 interact biochemically.
In addition PRMT7 shows a strong nuclear signal in
TCam-2 cells (Fig. 4I–M). These results indicate that in
germ cell tumors, both PRMT5 and PRMT7 might cooper-
ate with BLIMP1 to establish dimethylation of H2A and
H4.
Discussion
In this study, we analyzed the expression of the putative
inhibitor complex of germ cell differentiation BLIMP1
and PRMT5 on mRNA and protein level and the presence
of the resulting repressive histone modifications H2A/
H4R3me2s in human fetal and adult germ cells as well as
TGCTs. We found BLIMP1 and PRMT5 localized in the
nuclei of gonocytes, and the latter also in the cytoplasm,
and could show the presence of the resulting dimethyla-
tion of H2A/H4 at arginine 3. In IGCNU a strong nuclear
signal of BLIMP1 and of H2K3me2s/H4K3me2s was
detected, whereas PRMT5 signal was cytoplasmatic in
IGCNU and heterogeneous in seminomas.
The expression in fetal gonocytes in humans described
here is in concordance to the observations made in mouse
[17] indicating a conserved role of the nuclear localized
BLIMP1/PRMT5 complex between mouse and man.
Recently the transcriptional repressor BLIMP1 has been
shown to be a crucial determinant of the germ cell lineage
in mice [16]. This Krüppel-type zinc-finger containing
protein interacts with the arginine methyl-transferase
PRMT5 resulting in a symmetrical methylation at arginine
3 of histone H4 and H2A (H4R3me2s/H2Ame2s). The
methylation in turn represses transcription[17] and there-
Table 1: Expression of BLIMP1, PRMT5 and dimethylated histone H4/H2A in normal and neoplastic testicular tissues
BLIMP1 PRMT5 H4R3me2s/H2Ame2s
Normal fetal testis
Gonocytes +++ (n) +++ (n,c) +++ (n)
Pre-spermatogonia - -
Normal adult testis (N = 18)
Spermatogonia - - ++ (n)
Pachytene spermatocytes - + (n) -
Round spermatids + (n,c) ++ (n) ++ (n)
Elongated spermatids - - -
Testicular germ cell tumors
IGCNU (N = 15) +++ (n)
85–100%
+++ (c)
75–95%
+++ (n)
90–100%
Seminoma (N = 20) ++ (n)
10–75%
++ (n+c)
30–85%
++ (n)
20–80%
Embryonal carcinoma (N = 15) +/-(c)*
15–80%
++ (c)
15–80%
(+)*
Teratoma (N = 5) + (n, c) + (n, c) + (n)
Chorioncarcinoma (N = 3) + (c) - -
N, number of cases; n, nuclear staining; c, cytoplasmatic staining
+ weak; ++ moderate; +++, strong expression; -, no expression detectable
*, only single tumor cells were detected as positive.BMC Developmental Biology 2008, 8:106 http://www.biomedcentral.com/1471-213X/8/106
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fore might be important for suppressing the somatic cell
fate and keeping germ cells in a pluripotent state. In fact,
in mice Blimp1-deficent germ cells show inconsistent
repression of HoxB1, a hallmark of germ cell specification
and fail to express Stella a marker of undifferentiated germ
cells [16]. Also, recent studies showed, that abrogation of
the Drosophila melanogaster homolog of PRMT5, Capsu-
leen/dart5, is essential for germ cell specification and
maintenance [25,26]. Interestingly, Blimp1 expression is
lost in PGCs which are cultured in the presence of basic
FGF and LIF [15] and gradually become embryonic germ
cells [27-29]. Hence the BLIMP1/PRMT5 interaction
resulting in H2A/H4 modification might lead to repres-
sion of premature differentiation during human fetal
germ cell development. As a consequence prolonged
expression of BLIMP1/PRMT5 could result in persistence
of undifferentiated gonocytes into adulthood.
It is believed that those persisting gonocytes give rise to
IGCNU the common precursor lesion of all type II TGCTs
Analysis of TCam-2 seminoma cell line Figure 5
Analysis of TCam-2 seminoma cell line. (A-B) Immunohistochemistry using the antibodies indicated. (C) Merge of (A) 
and (B). (D) Counterstaining with DAPI to detect nuclei. (E) RT-PCR cell lines TCam2 and JKT1 as well as Testis detecting 
expression of the indicated genes. (F) Western Blot of protein lysate from TCam2 cells detecting the proteins indicated. (G) 
Co-IP experiment using antibody to PRMT5 for IP and antibody to BLIMP-1 to detect potential interaction. – no Antibodyl; + 
IP using PRMT5 Antibody; Input Control. (H) Co-IP experiment using antibody to PRMT7 for IP and antibody to BLIMP-1 to 
detect potential interaction. – no Antibodyl; + IP using PRMT5 Antibody; Input Control. (I-M) Immunohistochemistry using the 
PRMT7 antibody (I), (K) Merge of (I) and (M), (L) Counterstaining with DAPI to detect nuclei, (M) brightfield image. Scale Bar 
indicates 25 μm.BMC Developmental Biology 2008, 8:106 http://www.biomedcentral.com/1471-213X/8/106
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[4]. Indeed, we detected BLIMP1 protein and the charac-
teristic modification of histones H2A and H4 not only in
gonocytes but also in IGCNU and in seminoma support-
ing a PGC/gonocyte origin of IGCNU and therefore GCT
[5,8,30,31]. PRMT5 however, is not detectable in nuclei of
IGCNU, and displays only a sparse nuclear localization in
seminoma cells. We found that another type II protein
arginine methyltransferase, PRMT7 is expressed in
TCAM2 seminoma cells and that PRMT7 interacts with
BLIMP1 as well. So we speculate that in IGCNU and sem-
inoma, BLIMP1 recruits PRMT7 to compensate for the
lack of nuclear PRMT5 to mediate H2A and H4 dimethyl-
ation.
Upon progression of IGCNU to nonseminomas signal
intensity of BLIMP1 decreased and subcellular localiza-
tion changed. As a consequence, H2A/H4 modification
decreased and became heterogeneous in nonseminomas.
Hence, the loss of the repressive histone modifications
allows further uncontrolled differentiation observed in
nonseminomas.
Conclusion
Taken together we propose the following model for devel-
opment of germ cell neoplasia. First, coexpression and
nuclear localization of the BLIMP1/PRMT5 complex leads
to histone H2A/H4 dimethylation which results in tran-
scriptional silencing of genes responsible for somatic dif-
ferentiation in PGCs. Upon differentiation to
prespermatogonia, this complex is downregulated and the
H2A/H4 marks are lost. Aberrant constitutive histone
H2A/H4 arginine 3 dimethylation allows the cells to
escape the regular differentiation program resulting in
their persistence into adulthood. These cells eventually
progress into IGCNU, displaying the H2A/H4R3me2s
modification as well. Since the subcellular localization of
PRMT5 excludes PRMT5-dependent histone H2A/H4
modification in IGCNU we propose that BLIMP1 might
act in cooperation with PRMT7. This mechanism persists
in seminoma where the H2A/H4R3me2s modifications
can be observed which explains the undifferentiated
nature of the tumor cells. Translocation of BLIMP1 into
the cytoplasm leads to breakdown of histone H2A/H4
dimethylation and subsequently to the activation of the
differentiation programs and therefore the conversion
from IGCNU into a nonseminomatous germ cell tumors.
Methods
Sample Handling and Characterization
Formalin fixed, paraffin embedded testicular tissues from
46 patients with GCTs (20 seminomas, 15 embryonic car-
cinomas, 5 Teratomas, 3 yolk sac tumors and 3 choriocar-
cinomas were collected for this study from archives of
Departments of Pathology of University Medical Centers
Bonn. Adjacent testicular parenchyma containing IGCNU
were studied in 15 cases[32]. All tumors were classified
according to the WHO classification of tumors based on
their histology by two independent pathologists. Fresh
frozen samples of each of normal testicular tissues (n = 3),
seminoma (n = 3), mixed germ cell tumors (n = 3),
IGCNU (n = 5) and embryonal carcinomas (EC) (n = 3),
as well as RNA extracts of TCam2 [33] and JKT-1[34] cell
lines, of which TCam2 resembles a seminoma-like cell-
line [21-23], were additionally available for this study.
Use of the tissue for scientific purposes was approved by
the Institutional Regional Committee for Ethics.
RT-PCR and quantitative image analysis
Total RNA from at least three samples per tumor entity
was extracted with TRIzol (Invitrogen, Karlsruhe, Ger-
many) according to manufacturer's instruction. cDNA-
syntesis was performed using SuperScript III reverse tran-
scriptase (Invitrogen, Karlsruhe, Germany) and Oligo
d(T)12–18(Invitrogen, Karlsruhe, Germany) and 100 ng of
total RNA according to manufacturers instructions. PCRs
were carried out in triplicates with following Primers:
BLIMP1  F: 5'-GGGTGCAGCCTTTATGAGTC-3'; BLIMP1
R: 5'-CCTTGTTCA TGCCCTGAGAT-3'; PRMT5  F:
5'TTGCCGGC TACTTTGAGACT-3'; PRMT5  R: 5'-AAG-
GCAGGA AAGCAGATTGA-3'; GAPDH-F: 5'-TGG-
TATCGTGGAA GGACTCATG AC-3; GAPDH R: 5'-ATGCC
AGTGAGCTTCCCGTTCAGC-3'. (β-Act: 25 cycles BLIMP1
and PRMT5: 30 cycles). After agarose gel electrophoresis
of the PCR-products band intensity was measured after
RT-PCR with the image analysis software ImageJ 1.37 v
(National Institutes of Health, USA, http://
rsb.info.nih.gov/ij/) in triplicates and normalized to the
according GAPDH band.
Co-Immunoprecipitation
Co-IP was performed with DYNABEADS®  (Invitrogen,
Carlsbad, USA) following manufacturers instructions.
Immunopreciptation was performed with 1,5 μg anti-
PRMT5 antibody (Chemicon, Temecula, USA) or anti-
PRMT7 (Abcam, Cambrigde UK, 1:250). Western Blot
with anti-BLIMP1 antibody followed (provided by H. M.
Jäck).
Western Blot
For protein analysis Mini-PROTEAN Electrophoresis Cell
and Mini Trans-Blot system was used (BioRad, Munich,
Germany). Proteins were isolated using RIPA-buffer and
prepared using standard protocol and finaly electro-
phoresed at 30 mA for 90 min. The gel was blotted onto a
PVDF membrane in a BioRad blotting chamber overnight
at 30 V at 4°C according to published protocols. After
blocking in PBSTM (PBS, 0.1% v/v Tween 20, 5% low fat
milk powder) primary antibodies (anti-BLIMP1 1:400
(kind gift from H. Jäck), anti-PRMT5 1:200, Chemicon
International, USA) were incubated in PBSTM for 3 h atBMC Developmental Biology 2008, 8:106 http://www.biomedcentral.com/1471-213X/8/106
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RT. The secondary antibodies (anti-rabbit-HRP, anti-
mouse-HRP: DAKO, Hamburg, Germany) were diluted
1:2000. Finally the membrane was incubated in 2 ml
PierceSuper Signal West Pico chemiluminescent substrate
(Perbio, Bonn, Germany) and the signal was detected
using Kodak X-Ray film (Kodak, Stuttgart, Germany).
Array Analysis
DNA Array Dataset used to analyze BLIMP1/PRMT5
expression in Seminoma, embryonal carcinoma, TCam2
and JKT1 were generated as described [32].
Immunohistochemistry
For immunohistochemistry on paraffin-embedded tissue,
dewaxed, 4-μm thick tissue sections were microwave-pre-
treated in citrate-buffer. Primary antibodies to PRMT5
(Upstate, Charlottesville, VA, 1:500), PRMT7 (Abcam,
Cambrigde UK, 1:250) BLIMP1 (provided by H-M. Jäck,
University of Erlangen, Germany 1:500) and
H2AR3me2s/H4R3me2s (Abcam, Cambridge, UK,
1:2000) were used for detection. Immunohistochemistry
was performed using the DAKO EnVision-AEC Kit and
manufacturers protocol (DAKO, Hamburg, Germany) as
previously described [7]. Briefly, endogenous peroxidase
was blocked for 5 min in 0.03% H2O2 (diluted in distilled
water). Sections were washed in Tris-buffered saline (TBS;
0.05 M Tris and 0.85% NaCl, pH 7.6) and incubated with
primary antibodies overnight at 4°C. Thereafter, a HRP-
labeled polymer conjugated with a secondary antibody
was applied (DAKO EnVision-AEC KIT). Pictures were
taken using a Leica microscope fitted with a JVC digital
camera (Leica, Bensheim, Germany). Figures were assem-
bled using Adobe CS3 software package. Merge of pictures
was performed using ImageJ (NIH, US).
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